Hepatitis D News and Research

RSS

Hepatitis D is a viral infection that causes liver inflammation (swelling of the tissue which occurs due to injury or infection) and damage.

Increased IR associated with HCC development in chronic HCV-infected patients

Recent studies have demonstrated that type 2 diabetes mellitus (DM) is associated with high risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Insulin resistance (IR), which correlates inversely with circulating adiponectin concentration, is a consistent finding in patients with type 2 DM.

13 May 2010

Sex can affect frequency and severity of adverse effects of vaccination

Biological differences between the sexes could be a significant predictor of responses to vaccines, according to researchers at the Johns Hopkins Bloomberg School of Public Health. They examined published data from numerous adult and child vaccine trials and found that sex is a fundamental, but often overlooked predictor of vaccine response that could help predict the efficacy of combating infectious disease.

13 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported

Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.

12 May 2010

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Today, the biotech-vaccine company Intercell AG announced its financial results for Q1 and presented an update on the Company's development programs.

11 May 2010

Lawsuit over hepatitis C infections contracted from Doctor

Nearly 30 women got infected with Hepatitis C virus due to a breach in infection prevention protocols by an anaesthetist at a late-term abortion clinic. The incidents occurred at the Croydon Day Surgery in Melbourne's eastern suburbs during an 18-month period when James Latham Peters was working as an anaesthetist. The issue had come to light in the last few weeks. Now a multi million dollar lawsuit against the Medical Practitioners Board of Victoria on behalf of the allegedly infected women is being planned.

9 May 2010

Nokia launches Ovi Life Tools in China

Nokia today announced the launch of Ovi Life Tools in China. Designed for the emerging markets, Ovi Life Tools offers a wide range of information services covering healthcare, agriculture, education and entertainment.

7 May 2010

New CD4 test kit can improve quality of life for HIV and AIDS patients

The use of rapid point-of-care diagnostic tests for the measurement of CD4 T-cells, a marker of the immune system will be an important factor in improving the lives of people living with HIV and AIDS especially in developing and resource-poor countries.

7 May 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2010.

6 May 2010

Hepatitis B treatment appears to improve liver transplant outcomes for some patients: Study

Treatment to reduce recurrence of hepatitis B appears to improve liver transplant outcomes for some patients, according to a Mayo Clinic study presented at the American Transplant Congress under way May 1-5 in San Diego.

5 May 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week 2010 in New Orleans, Louisiana.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Clinical development of RG7128 is on track: Pharmasset

Pharmasset, Inc., in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program.

4 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

AIDS 2010 to explore latest developments in HIV science

Organizers of the XVIII International AIDS Conference announced today that President Bill Clinton, founder of the William J. Clinton Foundation and 42nd President of the United States, and South African Health Minister Aaron Motsoaledi will be among 19 high-level speakers who will address an estimated 25,000 conference attendees in Vienna this summer.

4 May 2010